Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FKS518

Monoclonal antibody · Antagonist of RANKL (TNFSF11) (TNFSF11) · developed by Fresenius Kabi SwissBioSim GmbH

Phase 3 Most advanced trial (none active)
FMS Developer
1 Registered trials

What is FKS518?

FKS518 is a denosumab biosimilar given subcutaneously by prefilled syringe. It is studied in postmenopausal osteoporosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Denosumab biosimilar
Drug type
Monoclonal antibody
Targets
RANKL (TNFSF11) (TNFSF11)
Mechanism
Antagonist of RANKL (TNFSF11) (TNFSF11)
Therapy area
Musculoskeletal
Developer
Fresenius Kabi SwissBioSim GmbH (FMS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04934072 Phase 3 Postmenopausal Osteoporosis Completed FMS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Postmenopausal Osteoporosis

Other drugs acting on TNFSF11

More from Fresenius Kabi SwissBioSim GmbH

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the FMS page.

Follow FMS, the company behind FKS518

See FMS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FMS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.